Health
Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape
The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.
After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…
-
Noosa News13 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General11 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News21 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
General19 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965